Genmab A/S ADS (GMAB) Stock
Key stats
- Market cap
- $33.22B
- Price / Earnings ratio
- 46.3x
- EPS (TTM)
- $1.19
- Volume
- Loading
- 52-week high
- $59.97
- 52-week low
- $23.62
Source: third-party data provider, as of November 13, 2026
Compare with GMAB
Recent news

A little-known biotech's high-stakes cancer bet just paid off and its shares doubled
A little-known biotech's high-stakes cancer bet just paid off and its shares doubled
GMAB

Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?
Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?
GMAB

Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches
Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches
GMAB

GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know
GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know
GMAB
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 67.07
- MACD 12/26/9
- 4.65
- EMA 9 of MACD
- 4.64
- MACD histogram
- 0.01
- SMA 50
- $40.46
- Price above SMA 50
- EMA 50
- $42.81
- Price above EMA 50
- SMA 200
- $31.36
- Price above SMA 200
- EMA 200
- $34.11
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

A little-known biotech's high-stakes cancer bet just paid off and its shares doubled
A little-known biotech's high-stakes cancer bet just paid off and its shares doubled
GMAB

Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?
Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?
GMAB

Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches
Genmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches
GMAB

GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know
GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know
GMAB

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
GMAB

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy
GMAB

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
GMAB

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
GMAB

Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
GMAB

AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL
AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL
GMAB
News tone: automated (AI) classification of the article's content, not a price prediction.
About Genmab A/S ADS
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, President & CEO | 1961 |
| Mr. Anthony Pagano CPA | Executive VP & CFO | 1978 |
| Mr. Rayne Waller | Executive VP & Chief Technical Operations Officer | 1968 |
| Mr. Gregory David Emil Mueller | Executive VP, General Counsel & Chief Legal Officer | 1971 |
| Mr. Christopher Cozic | Executive VP & Chief People Officer | 1978 |
| Dr. Martine J. van Vugt Ph.D. | Executive VP & Chief Strategy Officer | 1971 |
| Mr. Martin Schultz | Senior Director, Head of Development Business Partnership & Strategy and Director | 1975 |
| Dr. Judith V. Klimovsky M.D. | Executive VP & Chief Development Officer | 1958 |
| Dr. Tahamtan Ahmadi M.D., Ph.D. | Executive VP, Chief Medical Officer & Head of Experimental Medicines | 1973 |
| Dr. Mijke Zachariasse Ph.D. | VP, Head of Antibody Research Materials & Director | 1973 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 67.07
- MACD 12/26/9
- 4.65
- EMA 9 of MACD
- 4.64
- MACD histogram
- 0.01
- SMA 50
- $40.46
- Price above SMA 50
- EMA 50
- $42.81
- Price above EMA 50
- SMA 200
- $31.36
- Price above SMA 200
- EMA 200
- $34.11
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $45.00
- Average
- $61.83
- High
- $80.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -6.4 | +4.1 | ||||||||||
| 2022 | -14.1 | -3.4 | +6.3 | -4.0 | -13.1 | +8.2 | +6.6 | +1.2 | -9.9 | +13.9 | +21.3 | -8.6 |
| 2023 | -9.0 | -4.0 | +2.1 | +9.2 | -4.0 | -3.4 | +8.4 | -4.5 | -8.1 | -17.1 | +9.2 | -0.4 |
| 2024 | -14.0 | -1.4 | +2.1 | -8.5 | -1.9 | -12.8 | +13.8 | -1.9 | -11.1 | -7.6 | -4.7 | -4.4 |
| 2025 | -6.3 | +18.7 | -14.7 | +13.3 | +0.1 | -5.1 | +4.5 | +14.2 | +18.5 | -9.9 | +12.7 | -1.9 |
| 2026 | +2.5 | -11.5 | -9.5 | -2.6 | -0.5 | +7.9 | +4.5 | +15.6 | +7.2 | +65.2 | -1.9 |



